SCHEMBL25495348

SCHEMBL25495348

CC(C)OC1O[C@H](CCP(=O)(O)O)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IGF2R P11717 7/20 0.59
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
PRKCB P05771 1/20 0.39
PRKCA P17252 1/20 0.39
PRKCH P24723 1/20 0.39
PRKCI P41743 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39
PRKCZ Q05513 1/20 0.39
PRKCD Q05655 1/20 0.39
PRKD1 Q15139 1/20 0.39
P2RY2 P41231 3/20 0.37
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
FBP1 P09467 1/20 0.34
TYR P14679 2/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25494488 1.00 IGF2R (0.59) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL25083591 0.90 IGF2R (0.48) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL6933249 0.86 IGF2R (0.43) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL10259213 0.84 IGF2R (0.42) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL25499079 0.83 IGF2R (0.64) IGF2RP2RY2CA1CA2CA9
SCHEMBL1786879 0.83 IGF2R (0.64) IGF2RP2RY2CA1CA2CA9
SCHEMBL21711050 0.83 IGF2R (0.64) IGF2RP2RY2CA1CA2CA9
SCHEMBL23743570 0.80 IGF2R (0.69) IGF2RP2RY2CA1CA2CA9
SCHEMBL23322953 0.79 FBP1 (0.62) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL26951662 0.79 IGF2R (0.59) IGF2RP2RY2FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates M6PR, ASGR1, IGF2R IGF2R 3/4885PRKD3 2461/4885PRKCG 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.